Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult ALL Patients and Related Diseases with Biomaterial Collection

What this Trial Is About

Researchers are collecting information on adults diagnosed with Acute Lymphoblastic Leukemia ALL and related diseases like certain types of Non-Hodgkins Lymphoma. This observational registry gathers data from routine clinical care to support research and improve quality assurance. The study includes adults treated according to ALL or related treatment protocols, whether they are part of a clinical trial or not. This registry does not involve any specific treatments but collects detailed data on diagnosis, treatment, and outcomes. It prospectively gathers information on patient progress, including survival and remission rates, as well as biomaterial samples when available. The study monitors various types of leukemia and lymphoma subtypes treated under ALL protocols. Participants contribute by allowing their medical data and biomaterial to be collected and analyzed over time. Researchers track many outcomes such as overall survival, remission status, relapse rates, quality of life, and treatment-related side effects. Follow-up can extend up to 10 years, with ongoing evaluations to understand long-term health and treatment effects.

GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial